Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849278 | 0.82 | MEN1 (0.61) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL8854032 | 0.80 | KMT2A (0.48) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL4529320 | 0.79 | MEN1 (0.57) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL4099538 | 0.79 | KMT2A (0.57) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL10457090 | 0.77 | MEN1 (0.65) | KMT2AMEN1POLBKDM4ETSHR | |
| Hydrochloric Acid SCHEMBL7319435 | 0.77 | KMT2A (0.56) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL2746644 | 0.77 | CA2 (0.50) | KMT2AMEN1TSHRTDP1NR1H4 | |
| SCHEMBL10457088 | 0.76 | KMT2A (0.62) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL11355706 | 0.75 | MEN1 (0.57) | KMT2AMEN1POLBKDM4ETSHR | |
| SCHEMBL8689095 | 0.75 | MEN1 (0.62) | KMT2AMEN1POLBKDM4ENR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | KMT2A 1830/4885MEN1 4876/4885POLB 1041/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | KMT2A 1426/4885MEN1 4870/4885POLB 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.